PACB Pacific Biosciences of California, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PACB matters now
Pacific Biosciences of California, Inc. (PACB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.56 with -3.11% on the session and $484.5M in market capitalization; recent performance reads 1-month +21.74% and YTD -25.13%.
The latest financial table shown here is Q1 2026, with revenue of $37.2M, net income of $-8.3M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -26.7%.
The latest indexable market news headline is "Here's Why You Should Add PacBio Stock to Your Portfolio Now" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $1.00; recent insider activity includes ORDONEZ KATHY filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
180.96
P/S
2.72
EV/EBITDA
-10.15
DCF Value
$-10.51
FCF Yield
-26.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.1%
Operating Margin
-101.7%
Net Margin
-80.3%
ROE
-488.4%
ROA
-16.4%
ROIC
-22.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $37.2M | $-8.3M | $-0.03 |
| Q4 2025 | $44.6M | $-40.4M | $-0.13 |
| FY 2025 | $160.0M | $-546.4M | $-1.82 |
| Q3 2025 | $38.4M | $-38.0M | $-0.13 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$1.00
Target (Median)
$1.00
Target Range
$1.00 - $1.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
2.32
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.